✨ Innovation alert: CellEKT, developed by the lab of Oncode Investigator Mario van der Stelt & Oncode Researcher Joel Rüegger (both at @unileiden.bsky.social ), uses advanced probes to profile kinase inhibitor selectivity, supporting safer, targeted cancer therapies. Read more: lnkd.in/gxCBtu7W

€3M in funding for rare cancer therapies — REACT-NL call is now open! Oncode Institute, KWF Kankerbestrijding, and KiKa launch REACT-NL under Health~Holland 2025 PPP.

👉 €3M funding
👉 Deadline: Sept 2025
👉 Eligible: Dutch public-private consortia

Read more:
oncodeinstitute.nl/news/react-n...